Mild cognitive impairment
Conditions
Interventions
DHA intervention group:DHA soft capsules 1g/day (1g/capsule, 1 capsule/day)
Placebo control group:1 DHA placebo capsule per day.
Sponsors
Tianjin Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The participants themselves or confirmed by family members or doctors objectively believed that there was memory decline; 2. The course of memory decline lasted for at least three months; 3. The Mini-Mental State Examination (MMSE) score was >= 17 for the illiterate group, >= 20 for the primary school group, and >= 24 for the secondary school and above group; 4. According to the Activities of Daily Living Scale measurement, there was no or slight impairment in daily activities, and the ADL score was <= 18; 5. It did not meet the criteria for dementia, AD, mental illness, brain injury or any condition that may cause cognitive impairment and any active neuro-psychiatric disease. The diagnostic criteria for dementia were based on the DSM-IV standards of the American Psychiatric Association and the standards of the American Neurology, Language Disorders and Stroke - Geriatric Dementia and Related Diseases Society (NINCDS-ADRDA), combined with medical history and other data for dementia diagnosis. HIS was used to differentiate AD and vascular dementia. Suspected MCI and senile dementia patients were further diagnosed by neurologists.
Exclusion criteria
Exclusion criteria: 1. The neurological examination shows obvious signs of focal central nervous system disorders such as hemiplegia, hemiplegic sensory impairment, aphasia, etc. There is a history of cerebrovascular diseases (including hemorrhagic and ischemic types), as well as internal brain trauma or fractures. 2. Asthmatic bronchitis, severe hypertension, angina pectoris, and severe infections, etc. are among the internal medical conditions. 3. Psychiatric patients with obvious depression, anxiety, etc., and other histories of endocrine system diseases (such as hyperthyroidism, hypothyroidism, systemic lupus erythematosus, rheumatoid arthritis, etc.). 4. Newly discovered, advanced or terminal tumors. 5. Visual, auditory impairments or difficulties in language communication that significantly affect cognitive function tests. 6. History of alcohol dependence and other substance abuse disorders (such as antipsychotic drugs, benzodiazepines, etc.), or the use of drugs that affect cognitive function.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Full intelligence quotient; | — |
Secondary
| Measure | Time frame |
|---|---|
| Ferroptosis-Related Biomarkers;Serum Oxidative Stress Indicators;Basic Information of the Research Subjects; | — |
Countries
China
Contacts
Public ContactFei Ma
Tianjin Medical University
Outcome results
None listed